PMID- 37699302
OWN - NLM
STAT- Publisher
LR  - 20231017
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 124
IP  - Pt A
DP  - 2023 Nov
TI  - Tanshinone I attenuates gastric precancerous lesions by inhibiting epithelial 
      mesenchymal transition through the p38/STAT3 pathway.
PG  - 110902
LID - S1567-5769(23)01227-4 [pii]
LID - 10.1016/j.intimp.2023.110902 [doi]
AB  - BACKGROUND: Gastric precancerous lesions (GPLs) are omens for gastric cancer 
      (GC), which developing with a series of pathological changes of gastric mucosa. 
      Reversing epithelial-mesenchymal transition (EMT) in gastric mucosa is the main 
      approach to restrain GPLs from evolving into cancer. Tanshinone I (Tan-I), the 
      active ingredients of traditional Chinese herb Salvia miltiorrhiza, has exhibited 
      anticancer effect. PURPOSE: To investigate the effect and mechanism of Tan-I in 
      intervening GPLs, and provide a new therapeutic strategy for prevention of GC. 
      METHODS: Gastric mucosal epithelial cells were treated with the 
      N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) to construct MNNG-induced cell (MC 
      cell) of gastric mucosa that undergoing EMT process. Then, this study explored 
      the effect and mechanism of Tan-I in vitro. Subsequently, this study constructed 
      GPL mice to clarify the exact efficacy and mechanism of Tan-I on GPLs. RESULTS: 
      Tan-I inhibited MC cell proliferation, invasion and migration. Simultaneously, 
      the aberrant expression of E-cadherin and N-cadherin were reversed. Tan-I 
      attenuated inflammation by reducing the release of nitric oxide, TNFalpha and IL-1beta. 
      Tan-I reversed the EMT and inflammatory processes by regulating p38 and STAT3. 
      CONCLUSION: This study showed that Tan-I inhibited the progression of GPLs by 
      reversing the EMT process and reducing inflammation by restraining the p38/STAT3 
      signaling pathway.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Liang, Dan
AU  - Liang D
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Tang, Shiyun
AU  - Tang S
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Liu, Lu
AU  - Liu L
AD  - College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 
      China.
FAU - Zhao, Maoyuan
AU  - Zhao M
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Ma, Xiao
AU  - Ma X
AD  - College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 
      China.
FAU - Zhao, Yanling
AU  - Zhao Y
AD  - Department of Pharmacy, Chinese PLA General Hospital, Beijing, China.
FAU - Shen, Caifei
AU  - Shen C
AD  - Department of Endoscopy Center, Hospital of Chengdu University of Traditional 
      Chinese Medicine, Chengdu, China.
FAU - Liu, Qingsong
AU  - Liu Q
AD  - Department of Gastroenterology, Hospital of Chengdu University of Traditional 
      Chinese Medicine, Chengdu, China.
FAU - Tang, Jianyuan
AU  - Tang J
AD  - TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of 
      Chengdu University of Traditional Chinese Medicine, Chengdu, China. Electronic 
      address: tangjy@cdutcm.edu.cn.
FAU - Zeng, Jinhao
AU  - Zeng J
AD  - Department of Gastroenterology, Hospital of Chengdu University of Traditional 
      Chinese Medicine, Chengdu, China. Electronic address: zengjinhao@cdutcm.edu.cn.
FAU - Chen, Nianzhi
AU  - Chen N
AD  - State Key Laboratory of Ultrasound in Medicine and Engineering, College of 
      Biomedical Engineering, Chongqing Medical University, Chongqing, China. 
      Electronic address: saber930607@163.com.
LA  - eng
PT  - Journal Article
DEP - 20230910
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
SB  - IM
OTO - NOTNLM
OT  - Epithelial-mesenchymal transition
OT  - Gastric cancer
OT  - Gastric precancerous lesions
OT  - Tanshinone I
OT  - p38/STAT3
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/09/13 00:42
MHDA- 2023/09/13 00:42
CRDT- 2023/09/12 18:02
PHST- 2023/06/14 00:00 [received]
PHST- 2023/09/01 00:00 [revised]
PHST- 2023/09/03 00:00 [accepted]
PHST- 2023/09/13 00:42 [pubmed]
PHST- 2023/09/13 00:42 [medline]
PHST- 2023/09/12 18:02 [entrez]
AID - S1567-5769(23)01227-4 [pii]
AID - 10.1016/j.intimp.2023.110902 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2023 Nov;124(Pt A):110902. doi: 
      10.1016/j.intimp.2023.110902. Epub 2023 Sep 10.